Phase II Trial of Transarterial Embolization Using an n-Butyl-2-Cyanoacrylate/Lipiodol Mixture (JIVROSG-0802)
- 124 Downloads
To evaluate the embolic effect and the safety of transarterial embolization (TAE) using n-butyl-2-cyanoacrylate (NBCA) in a prospective multicenter trial.
Materials and Methods
This study was an open-label, multicenter, phase II trial. The inclusion criteria were (1) active bleeding or pseudoaneurysm, (2) true aneurysm, (3) arteriovenous malformation (except cerebral lesion), (4) arteriovenous fistula, or (5) need for arterial distribution before transarterial treatment. Selective TAE with NBCA diluted 2–10 times was performed. The primary endpoint was the success rate of embolization with a per-patient analysis based on the angiographic findings. Secondary endpoints were safety, evaluated based on Common Terminology Criteria for Adverse Events (CTCAE) version 4, and the success rate of embolization with a per-vessel calculation.
Sixty-five patients were initially enrolled, but due to protocol violation in two patients, efficacy was ultimately analyzed in 63 patients (103 vessels) and safety was analyzed in 64 patients. The success rate per patient was 98.4% (62/63; 95% confidence interval (CI), 91.5–100.00), and the success rate per vessel was 99.0% (102/103; 95% CI, 94.7–100.0). Adverse events of grade 3 or above based on CTCAE version 4 occurred in 22/64 patients (34.4%). Twelve intraoperative or postoperative adverse events grade 3 or above, which may have been related to embolization using NBCA, occurred in 11/64 patients (17.2%). Three patients died after embolization using NBCA, but their deaths were unrelated to TAE.
In this prospective multicenter clinical trial, the efficacy of TAE using NBCA was 98.4% and adverse events were clinically acceptable.
Level of Evidence
KeywordsTransarterial embolization NBCA Phase II study
This research was supported by the Practical Research for Innovative Cancer Control (16ck0106058h0003) from the Japan Agency for Medical Research and Development (AMED), Health and Labor Sciences Research Grant (H26-055) from the Ministry of Health, Labour and Welfare of Japan, and the National Cancer Center Research and Development Fund (26-A-27).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Consent for Publication
Consent for publication was obtained for every individual person’s data included in the study.
- 4.Arai Y. Glue. In: Marcelo Guimaraes RL, Gary P, editors. Embolization Therapy. 1st ed. Alphen aan den Rijn: Wolters Kluwer; 2015. p. 45–50.Google Scholar
- 6.Yonemitsu T, Kawai N, Sato M, Tanihata H, Takasaka I, Nakai M, et al. Evaluation of transcatheter arterial embolization with gelatin sponge particles, microcoils, and n-butyl cyanoacrylate for acute arterial bleeding in a coagulopathic condition. J Vasc Interv Radiol. 2009;20(9):1176–87. https://doi.org/10.1016/j.jvir.2009.06.005.CrossRefPubMedGoogle Scholar
- 8.Loh Y, Duckwiler GR, Onyx Trial I. A prospective, multicenter, randomized trial of the Onyx liquid embolic system and N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations. Clinical article. J Neurosurg. 2010;113(4):733–41. https://doi.org/10.3171/2010.3.JNS09370.CrossRefPubMedGoogle Scholar
- 9.n BCATI. N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations: results of a prospective, randomized, multi-center trial. AJNR Am J Neuroradiol. 2002;23(5):748–55.Google Scholar
- 13.Denys A, Lacombe C, Schneider F, Madoff DC, Doenz F, Qanadli SD, et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J Vasc Interv Radiol. 2005;16(12):1667–74. https://doi.org/10.1097/01.RVI.0000182183.28547.DC.CrossRefPubMedGoogle Scholar
- 15.Morishita H, Yamagami T, Takeuchi Y, Matsumoto T, Asai S, Nakanouchi T, et al. Use of N-butyl-2-cyanoacrylate for transcatheter arterial embolization of renal arteries in patients with polycystic kidney disease. J Vasc Interv Radiol. 2011;22(11):1631–3. https://doi.org/10.1016/j.jvir.2011.07.003.CrossRefPubMedGoogle Scholar
- 18.Kodani M, Yata S, Ohuchi Y, Ihaya T, Kaminou T, Ogawa T. Safety and risk of superselective transcatheter arterial embolization for acute lower gastrointestinal hemorrhage with n-butyl cyanoacrylate: angiographic and colonoscopic evaluation. J Vasc Interv Radiol. 2016;27(6):824–30. https://doi.org/10.1016/j.jvir.2016.01.140.CrossRefPubMedGoogle Scholar
- 19.Konas E, Canter HI, Cil B, Peynircioglu B, Karabulut E, Tuncbilek G, et al. Volumetric assessment of results of treatment of vascular malformations of the head and neck regions treated with a minimally invasive surgical technique after embolization procedure. J Craniofac Surg. 2009;20(2):402–5. https://doi.org/10.1097/SCS.0b013e31819b9400.CrossRefPubMedGoogle Scholar
- 21.Vanlangenhove P, De Keukeleire K, Everaert K, Van Maele G, Defreyne L. Efficacy and safety of two different n-butyl-2-cyanoacrylates for the embolization of varicoceles: a prospective, randomized, blinded study. Cardiovasc Intervent Radiol. 2012;35(3):598–606. https://doi.org/10.1007/s00270-011-0188-9.CrossRefPubMedGoogle Scholar
- 27.Hartmann A, Mast H, Mohr JP, Pile-Spellman J, Connolly ES, Sciacca RR, et al. Determinants of staged endovascular and surgical treatment outcome of brain arteriovenous malformations. Stroke. 2005;36(11):2431–5. https://doi.org/10.1161/01.STR.0000185723.98111.75.CrossRefPubMedGoogle Scholar
- 29.Institute NC. Common terminology criteria for adverse events (CTCAE) version 4.0. 2009. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40. Accessed 26 Nov 2018
- 31.Bent CL, Low D, Matson MB, Renfrew I, Fotheringham T. Portal vein embolization using a nitinol plug (Amplatzer vascular plug) in combination with histoacryl glue and iodinized oil: adequate hypertrophy with a reduced risk of nontarget embolization. Cardiovasc Intervent Radiol. 2009;32(3):471–7. https://doi.org/10.1007/s00270-009-9515-9.CrossRefPubMedGoogle Scholar
- 33.Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64. https://doi.org/10.1038/bjc.2014.199.CrossRefPubMedPubMedCentralGoogle Scholar